Roche Forges Ahead With Taspoglutide Despite Cancer Signal With Competitor GLP-1
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche expects Phase III data on the type 2 diabetes drug to be available by the end of the year and maintains that any carcinogenicity issue is rodent-specific.